ADVA
20.5.2021 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new compact, low-power edge demarcation solution, giving network operators an easy and cost-efficient route to 10Gbit/s Carrier Ethernet services. The ADVA FSP 150-XG108 Series meets the precise needs of mobile network operators (MNOs) aiming to deliver a faster and more responsive experience by rolling out 5G New Radio equipment at scale. The solution also enables enterprises to affordably extend bandwidth as they push data to the cloud and supports the cost-effective expansion of digitized cable networks. Featuring zero-touch provisioning and 5G timing capabilities, the ADVA FSP 150-XG108 Series is ideal for growing network capacity while reducing footprint, power and cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005061/en/
“Today’s MNOs need to be able to seize new revenue opportunities and grow capacity without worrying about increased energy consumption or rack space eating into profitability. That’s where our FSP 150-XG108 Series hits the sweet spot. It provides a quick and seamless way to deploy high-bandwidth Carrier Ethernet services without major cost,” said Christoph Glingener, CTO, ADVA. “Our FSP 150-XG108 Series is engineered for the practical challenges of meeting cloud and 5G demand. It consumes very little power and supports both 1Gbit/s and 10Gbit/s interface speeds in a 1RU footprint. What’s more, with its temperature-hardened design, our FSP 150-XG108 Series removes the need for expensive air-conditioning.”
The ADVA FSP 150-XG108 Series enables network operators to easily and affordably migrate from 1Gbit/s to 10Gbit/s MEF 3.0 services. Using proven and established OAM processes, it offers simple operation and network integration. With zero-touch provisioning, the ADVA FSP 150-XG108 Series removes the need for technically trained onsite staff and makes service activation quick and easy. Its compact design caters for space-restricted applications and its redundant power supply ensures high availability. The ADVA FSP 150-XG108 Series is also well prepared for emerging timing requirements with hardware-assisted BITS, PTP and SyncE synchronization.
“We’re providing the compact, robust and reliable demarcation that mobile, cable and enterprise networks require for massive 10Gbit/s rollout. Our FSP 150-XG108 Series is simple, efficient and highly scalable. With zero-touch provisioning, service activation becomes effortless. The FSP 150-XG108 Series also offers intuitive network control and service monitoring through the automated management of our Ensemble Controller and Ensemble Packet Director,” commented James Buchanan, GM, Edge Cloud, ADVA. “And, despite being optimized for cost-sensitive, high-bandwidth applications, our FSP 150-XG108 Series doesn’t compromise on performance or synchronization. It’s the perfect choice for empowering any network edge with 10Gbit/s demarcation and aggregation.”
Watch this product video for more information: https://youtu.be/pAcqPOtO5eI .
Additional details are also available in this Tech Cam interview: https://youtu.be/bdd-AqvgpBM .
Supporting slides can be viewed here: https://adva.li/fsp-150-xg108-series-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005061/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom